MHG  has sub-licensed its IP license agreement for fexofenadine patent to Celfex AB. The patent shall protect the IP around a topical lotion (stable formulation) of Fexofenadine for Atopic Dermatitis indication.  Celfex AB is an SPV which will be responsible to lead the development and commercialization of this product.  MHG as parent company will provide support as required for accelerated ‘time to value’.  Celfex AB will invite strategic investment and collaborating partners as its next phase of clinical development.   There is later the possibility to target a range of inflammatory skin disorders – as development continues, other target indications may emerge including CSU and Psoriasis.